Research programme : Purinergic P1 receptor modulators - Lewis and Clark Pharmaceuticals

Drug Profile

Research programme : Purinergic P1 receptor modulators - Lewis and Clark Pharmaceuticals

Alternative Names: Adenosine receptor modulators - Lewis and Clark Pharmaceuticals

Latest Information Update: 06 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Lewis and Clark Pharmaceuticals
  • Class Anti-inflammatories; Antiasthmatics; Antibacterials; Antiglaucomas; Antineoplastics
  • Mechanism of Action Adenosine A2A receptor agonists; Adenosine A2A receptor antagonists; Adenosine A2B receptor antagonists; Purinergic P1 receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Asthma; Atherosclerosis; Autoimmune disorders; Cancer; Clostridium infections; Fatty liver; Glaucoma; Inflammation; Pain

Most Recent Events

  • 02 Oct 2017 Inspyr Therapeutics enters into a research collaboration agreement with University of Virginia School of Medicine
  • 02 Oct 2017 Preclinical trials in Clostridium infections in USA (unspecified route)
  • 13 Sep 2017 Lewis and Clark Pharmaceuticals has been acquired by Inspyr Therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top